通讯作者: 毛宗福, zfmao@whu.edu.cn

DOI：10.12201/bmr.202401.00003

The impact of volume-based procurement policy on the pharmaceutical industry: A systematic review based on the SCP paradigm

• 摘要：目的：系统综述药品集中带量采购（以下简称“集采”）政策对我国医药产业的影响。方法：通过知网、万方、PubMed、Web of Science数据库检索2019年1月1日至2023年7月31日公开发表文献。借鉴市场结构（Structure）-企业行为（Conduct）-行业绩效（Performance）分析框架（简称“SCP范式”）构建主题框架进行资料整理分析。结果：纳入41篇文献，报告市场结构、企业行为、行业绩效三个维度影响的文献分别有10篇（24.4%）、24篇（58.5%）、23篇（56.1%），共提取10个二级主题。文献表明：市场结构上，集采政策后中标企业市场份额大幅提升，行业集中度明显提高；企业行为上，中标与非中标企业研发投入均增加，企业针对集采产品的销售投入削减，但非集采产品的销售投入未见减少；行业绩效上，集采政策对经营绩效的影响因企业而异，政策初步起到促进中标企业创新产出作用。结论：集采政策在优化市场结构、引导企业行为、提升行业绩效方面显现积极作用，为巩固和扩大政策影响，建议进一步强化药品价格综合治理，拓展集采市场边界，加强政策监测与追踪研究。

  关键词： 药品集中带量采购; 医药产业; 系统综述; SCP范式

   

  Abstract: Objective: To systematically review the impact of Chinese volume-based procurement (VBP) policy on the pharmaceutical industry. Methods: Relevant literature published between January 1, 2019 and July 31, 2023 were retrieved from the database of CNKI, WanFang data, PubMed, and Web of Science. A thematic analysis framework was constructed for data collation and analysis applying the Structure-Conduct-Performance (SCP) paradigm. Results: Forty-one studies were included, with 10 (24.4%), 24 (58.5%), and 23 (56.1%) reporting the dimension of structure, conduct, and performance, covering 10 secondary themes. Literature shows that, in terms of market structure, the market share of bid-winning enterprises increased after VBP policy, and the concentration ratio of pharmaceutical industry promoted; as for enterprise conduct, the R&D investment of both bid-winning and bid-non-winning enterprises increased under policy implementation, and the selling expenses on policy-covered products significantly reduced while policy-uncovered products did not; as for industry performance, the impact of VBP policy on operational performance varies among enterprise, and the initially positive effect on promoting innovative output of bid-winning enterprises was observed. Conclusion: The VBP policy has shown positive effects in optimizing market structure, guiding enterprise conduct, and improving industry performance. To consolidate and expand policy effects, it is recommended to further strengthen the comprehensive management of drug prices, expand the boundaries of the VBP market, and strengthen policy monitoring and tracking research.

  Key words: volume-based procurement; pharmaceutical industry; systematic review; SCP paradigm

  提交时间：2024-01-12

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 曾叙衡, 郑颐, 吕军, 宁玉玲, 励晓红. 实施高值医用耗材带量采购的SWOT分析——以上海市为例. 2020. doi: 10.12201/bmr.202010.00841

  孙文俊, 赵子寅, 成哲玉, 李慧宁, 祝贺. 药品集中采购政策对药品价格和使用影响的系统综述. 2023. doi: 10.12201/bmr.202303.00033

  刘明珠, 路云. 基于间断时间序列的国家药品集中带量采购协议期满品种接续工作实施效果研究——以河北省为例. 2023. doi: 10.12201/bmr.202306.00007

  孙言, 朱正, 杨莉. 国家组织药品集中带量采购价格降幅影响因素分析. 2022. doi: 10.12201/bmr.202203.00008

  韩朦, 王诗嘉, 胡皓钰, 赵艳蛟, 陈永法. 中成药集中带量采购分组规则对比研究. 2023. doi: 10.12201/bmr.202312.00008

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 国家组织药品带量采购政策的降价持续性研究. 2023. doi: 10.12201/bmr.202305.00008

  宋佳, 范成鑫, 王婉晨, 艾旭峰, 刘馨璐, 李翠玉, 张玉杰, 李秋莎, 王安琪, 丰志强, 尹文强, 马东平. 利益相关者视角下我国药品集中带量采购政策研究——基于政策工具的文本分析. 2022. doi: 10.12201/bmr.202203.00006

  唐玉清, 李胤铭, 陈西卓, 薛天琴, 陈昊. 基于政策执行系统模型的药品集中采购政策执行分析. 2023. doi: 10.12201/bmr.202310.00002

  马涵彬, 赵静, 管泳怡, 张枫怡, 杨立津, 刘森元. 基于政策工具的我国中医药产业化政策文本分析. 2023. doi: 10.12201/bmr.202304.00006

  王彪, 张天天, 唐啸宇, 贾韵, 罗力. 我国集中带量采购中选药品价格的差异及区域分布研究. 2023. doi: 10.12201/bmr.202306.00008

• 序号	提交日期	编号	操作
  1	2023-09-11	10.12201/bmr.202401.00003V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论